SK Plasma
- Biotech or pharma, therapeutic R&D
SK Plasma is a leading biopharmaceutical company dedicated to the development and commercialization of innovative plasma-derived therapies. With a commitment to improving patient outcomes, SK Plasma is committed to substantial investment in external R&D to drive innovation and bring new therapies to market.
SK Plasma is a subsidiary of the prestigious SK Group, the third largest business conglomerate in Korea with a revenue of 119 Billion USD in 2024.
In our pursuit of advancing healthcare, SK Plasma is actively exploring new therapeutic areas, including:
- Oncology
- Autoimmune diseases
- Blood related disorders
- Rare & Orphan diseases
SK Plasma is actively seeking in-licensing opportunities for cutting-edge therapies and strategic partnerships with R&D-focused biotech companies that possess strong technological capabilities. We invite potential partners to join us in our quest to transform lives through groundbreaking medical advancements.